Shilpa Medicare informs about updates

31 Oct 2024 Evaluate
Shilpa Medicare has informed that Shilpa Medicare, Unit VI, Dabaspet, Bengaluru, India was inspected by USFDA on 24, 25 and 28, 29, 30 October 2024. The inspection was the onsite GMP inspection of this Site. The inspection concluded with the issuance of Form 483 with four observations. All observations are procedural in nature. The Company shall respond to the observations within the time frame. This Unit of Shilpa Medicare Ltd. is engaged in the manufacturing, testing and release of Oral Mouth Dissolving Films and Transdermal Systems. The Site has already been approved by MHRA-UK and TGA Australia and has USFDA approval for supplying nutraceutical Oral Film products into US and other markets.

The above information is a part of company’s filings submitted to BSE.


Shilpa Medicare Share Price

935.80 55.90 (6.35%)
21-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1777.65
Dr. Reddys Lab 1194.55
Cipla 1465.65
Lupin 2043.30
Zydus Lifesciences 944.25
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.